LinkedIn facebook twitter youtube

Myeloma Patients Europe (MPE) will hold a panel event on “the perspectives of Minimal Residual Disease (MRD) in multiple myeloma” on Wednesday, 29 March 2023 from 15:00 – 16:30 CET.

MPE will present the findings of the research project and recommendations, followed by a panel discussion comprised of clinicians, patients, regulators and researchers to discuss the issues surrounding MRD.


Feel free to forward the registration link to colleagues and other patient advocates who might be interested in attending the webinar.

A recording of the webinar will be available here shortly after the session.

If you have any questions, please email research@mpeurope.org, and we will be in touch soon.


Project Background:

Patient and Haematologist Perspectives on Minimal Residual Disease Testing in Myeloma


Project Launch: April 2022

The study aimed to gain a deeper understanding of the patient experience and perspective of using minimal residual disease (MRD) status both in clinical trials as a primary endpoint, in health technology and regulatory assessments and as part of treatment decision making.

The broad research questions/aims of the study were to understand:

  • Are patients aware and educated of MRD?
  • What is their perspective on its importance?
  • Recognition on regulatory and health technology assessments
  • Impact on treatment decisions from clinicians and health care professionals
  • Perspectives of patients and health care professionals from different European countries
  • Impact on emotional wellbeing of knowing MRD status
  • What are the challenges around MRD recognition?


The outputs of this project expanded our knowledge of patients’ understanding of MRD, which highlighted gaps in educational materials related to this topic and will inform future research.

This project was managed and conducted by MPE.


The outputs of this project include:

  1. A report on the project findings with recommendations (published in March)
  2. Educational materials (released in March)
  3. An MRD Panel event


Thank you to Sanofi, Janssen and Sebia for funding this research project. MPE would like to extend a special thank you to the patients and clinicians who took part in this study, we are grateful for your time and generosity in sharing your experiences and insights. MPE would also like to thank the MRD Project Steering Committee for their expertise and continuous feedback throughout the project.